Last updated: February 19, 2026
This analysis summarizes the patent litigation between Novartis Pharmaceuticals Corporation and Alembic Pharmaceuticals Limited concerning the drug Entresto (sacubitril/valsartan). The core dispute centers on alleged infringement of U.S. Patent No. 9,511,010 by Alembic's proposed generic version of Entresto.
What is the Subject of the Litigation?
The litigation concerns U.S. Patent No. 9,511,010, owned by Novartis Pharmaceuticals Corporation, which covers the active pharmaceutical ingredient (API) combination of sacubitril and valsartan. This combination is marketed by Novartis as Entresto, indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Alembic Pharmaceuticals Limited is seeking to market a generic version of Entresto, and Novartis alleges that Alembic's proposed product infringes the '010 patent.
What are the Key Patents Involved?
The primary patent at issue in this litigation is U.S. Patent No. 9,511,010. This patent claims the compound N-(3-((4-((4-bromophenyl)amino)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-5-yl)methyl)phenyl)-3-(aminocarbonyl)propanamide, which is sacubitril. The patent also covers its salts, solvates, and mixtures. Entresto is a co-formulation of sacubitril and valsartan. Novartis also holds other related patents for Entresto, but the '010 patent has been central to the infringement actions.
What is the Basis of Novartis's Infringement Claim?
Novartis alleges that Alembic's proposed generic product will infringe U.S. Patent No. 9,511,010. Specifically, Novartis contends that Alembic's proposed generic drug contains the API sacubitril, which is claimed by the '010 patent. Novartis asserts that Alembic's proposed manufacture, use, sale, offer for sale, and importation of its generic drug product will directly infringe and/or be contributorily infringed and/or induce infringement of the '010 patent.
What is Alembic's Defense Strategy?
Alembic's defense strategy typically involves challenging the validity and/or enforceability of the asserted patent. This can include arguments such as:
- Non-infringement: Alembic may argue that its proposed product does not fall within the scope of the claims of U.S. Patent No. 9,511,010.
- Invalidity: Alembic may seek to invalidate the patent by asserting prior art that demonstrates the claimed invention was not novel or was obvious at the time of filing. This could involve demonstrating that sacubitril or its pharmaceutical equivalents were known or used before the patent's priority date.
- Patent Unenforceability: Alembic might argue that the patent is unenforceable due to issues such as inequitable conduct during prosecution before the United States Patent and Trademark Office (USPTO).
What is the Procedural History of the Case?
The case, Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited, was filed in the United States District Court for the District of New Jersey. The initial complaint was filed on December 6, 2019. This litigation is part of a broader strategy by Novartis to defend its Entresto patent portfolio against generic challenges. Many such challenges are initiated as Paragraph IV certifications under the Hatch-Waxman Act, where a generic company asserts that a listed patent is invalid, unenforceable, or will not be infringed by the generic product.
What are the Likely Outcomes and Timelines?
The outcome of patent litigation is inherently uncertain and can be influenced by numerous factors, including the strength of patent claims, the quality of prior art, the evidence presented by both parties, and the judge's or jury's interpretation of the law.
In cases involving Paragraph IV certifications, a common timeline can involve:
- Complaint Filing: Typically within 45 days of receiving a Paragraph IV notice from the generic company.
- Discovery: Extensive discovery, including document production, interrogatories, and depositions, can span several months to over a year.
- Markman Hearing (Claim Construction): The court interprets the meaning and scope of the patent claims. This hearing usually occurs several months before trial.
- Summary Judgment Motions: Parties may file motions for summary judgment, seeking to resolve certain issues without a trial.
- Trial: If the case is not settled or resolved through summary judgment, a trial can occur one to two years after the initial complaint.
- Appeals: Decisions can be appealed to the United States Court of Appeals for the Federal Circuit, adding significant time.
Given the complexities of patent law and the financial stakes involved, these litigations can be protracted. A preliminary injunction motion, if filed by Novartis, could seek to halt Alembic's activities during the pendency of the litigation.
What is the Market Impact of Entresto and its Generic Competition?
Entresto (sacubitril/valsartan) has been a significant commercial success for Novartis. It is a blockbuster drug with annual sales exceeding billions of dollars.
- Novartis: The continued exclusivity of Entresto allows Novartis to maintain its substantial revenue stream from the drug. The patent litigation is critical to preserving this revenue and protecting its market share.
- Generic Manufacturers (e.g., Alembic): Successful generic entry typically leads to a rapid and dramatic decrease in the price of the drug. This makes the medication more accessible and affordable for patients, while significantly impacting the innovator's sales.
The outcome of this litigation will determine when and under what conditions generic versions of Entresto can enter the U.S. market, directly influencing drug pricing and market dynamics.
What are the Settlement Possibilities?
Settlements are common in Hatch-Waxman litigation. Parties may reach an agreement to resolve the dispute outside of court. Settlement terms can vary widely, but often include:
- Entry Date: The generic manufacturer agrees to a specific date for market entry, which may be earlier than the patent expiration date but later than immediate entry.
- Licensing Agreements: The innovator company may grant a license to the generic manufacturer to produce and sell the drug after a certain period or under specific conditions.
- Confidential Terms: The financial and operational details of settlements are often confidential.
A settlement would avoid the costs and uncertainties of a trial and appeal process.
Key Takeaways
- Novartis is defending U.S. Patent No. 9,511,010 against Alembic Pharmaceuticals Limited's proposed generic version of Entresto (sacubitril/valsartan).
- Novartis alleges direct, contributory, and induced infringement of the '010 patent by Alembic's generic product.
- Alembic's defense likely centers on challenging the validity and enforceability of the '010 patent, potentially arguing non-infringement or prior art invalidity.
- The litigation is proceeding in the U.S. District Court for the District of New Jersey and is part of the broader Hatch-Waxman Act framework.
- The resolution of this case will significantly impact the market entry timeline and pricing of generic Entresto.
Frequently Asked Questions
1. What is the primary active ingredient claimed by U.S. Patent No. 9,511,010?
The primary active ingredient claimed by U.S. Patent No. 9,511,010 is sacubitril.
2. Under what legal framework is this type of patent litigation typically filed by generic companies?
This type of patent litigation is typically filed under the Hatch-Waxman Act, specifically through a Paragraph IV certification.
3. What are the potential consequences for Alembic if Novartis prevails in this litigation?
If Novartis prevails, Alembic may be permanently enjoined from manufacturing, using, selling, offering for sale, or importing its generic drug product that infringes the '010 patent.
4. Can Novartis seek damages in this case?
Yes, if infringement is found, Novartis can seek damages, which could include lost profits or a reasonable royalty.
5. What is the typical duration of patent litigation in the U.S. for pharmaceutical products?
Pharmaceutical patent litigation in the U.S. can typically last from one to several years, often involving appeals to the Federal Circuit.
Citations
[1] Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited, 1:19-cv-02021 (D.N.J. filed December 6, 2019).
